Probi AB (LTS:0GZB) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Probi AB Debt-to-Equity?

Probi AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr15.3 Mil. Probi AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr36.9 Mil. Probi AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr1,426.1 Mil. Probi AB's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Probi AB's Debt-to-Equity or its related term are showing as below:

LTS:0GZB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.25
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Probi AB was 0.25. The lowest was 0.02. And the median was 0.05.

LTS:0GZB's Debt-to-Equity is ranked better than
85.05% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs LTS:0GZB: 0.04

Probi AB Debt-to-Equity Historical Data

The historical data trend for Probi AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB Debt-to-Equity Chart

Probi AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.04

0.06

0.05

0.04

Probi AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.04	0.04	0.04

Competitive Comparison of Probi AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Probi AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Probi AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Probi AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Probi AB's Debt-to-Equity falls into.

Probi AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Probi AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.585	+	38.212)	/	1369.08
	=	0.04

Probi AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.29	+	36.905)	/	1426.132
	=	0.04

Probi AB (LTS:0GZB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Probi AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Probi AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Probi AB (LTS:0GZB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (LTS:0GZB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PBBIF:USA PROB:Sweden

Address

Ideongatan 1 A, Lund, SWE, SE-223 70

Website

https://www.probi.com

Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (LTS:0GZB) Headlines

No Headlines